# Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

> **NCT02663687** · PHASE1 · COMPLETED · sponsor: **Shire** · enrollment: 48 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** Recombinant human C1 esterase inhibitor
- **DRUG:** Placebo
- **DRUG:** SHP623
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02663687
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-19
- **Primary completion:** 2016-12-05
- **Final completion:** 2016-12-05
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02663687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02663687, "Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02663687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*